Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-31
2007-07-31
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10489344
ABSTRACT:
The present invention provides a polypeptide or a pharmacologically acceptable salt thereof comprising one or more, identical or different, amino acid sequences of A-W—H—X1-D-X2-X3-X4-W—W—X5-X6-X7-X8-B (the meaning of each symbol in the formula is defined in the description) and a pharmaceutical composition for treating an angiogenic disease such as a solid tumor comprising said polypeptide. The present invention also relates to a polynucleotide encoding the above-mentioned polypeptide and use of the polynucleotide in gene therapy.
REFERENCES:
patent: 6610836 (2003-08-01), Breton et al.
patent: WO 97/08313 (1997-03-01), None
patent: WO 01/72829 (2001-04-01), None
Sutter et al. “Gene therapy for gastric cancer: is it promising?” World J Gastroenterol., 2006, 12, 380-7.
Aslanidis et al. “Nucleotide sequences and operon structure of plasmid-borne genes mediating uptake and utilization of raffinose inEscherichia coli.” Journal of Bacteriology, 1989, 171, 6753-63.
Jekel et al. “Panulirus interruptus hemocyanin,” Eur. J. Biochem., 1988, 178, 403-12.
Liu et al. “Cancer gene therapy targeting angiogenesis: An updated review.” World J. Gastroenterol., 2006, 12, 6941-8.
Ginalski et al. “Practical lessons from protein structure prediction.” Nuc. Ac. Res., 2005, 33, 1874-1891.
Rudinger “Characteristic of the amino acids as components of a peptide hormone sequence.” (Peptide Hormones(Ed. J.A. Parson). University Park Press. Baltimore, 1976, pp. 1-7.
Pitt et al. “Single amino acid substitution mutants of Klebsiella pneumoniae singma54 defective in transcription” Nuc. Ac. Res., 2000, 28, 4419-4427.
Bradley et al. “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Subsitutions in Each Repeat” J. Mol. Biol., 2002, 324, 373-386.
Flanagan et al. “Truncated staphyloccal nuclease is compact but disordered” Proc. Natl. Acad. Sci. USA, 1992, 89, 748-752.
Sawai et al. “Impact of single-residue mutations on the structure and function of ovispirin
ovispirin antimicrobial peptides” Prot. Engin., 2002, 15, 225-232.
Schnog et al. “Sickle cell disease; a general overview” J. Med., 2004, 62, 364-374.
An Ping
Lei Hetian
Liu Xiaoying
Meng Lin
Shou Chengchao
Beijing Institute for Cancer Research
Bradley Christina Marchetti
Connolly Bove & Lodge & Hutz LLP
Tsang Cecilia J.
LandOfFree
Antagonist peptides to VEGF receptor Flt-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonist peptides to VEGF receptor Flt-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonist peptides to VEGF receptor Flt-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754785